Skip to main content
. 2021 Feb 6;6(2):100050. doi: 10.1016/j.esmoop.2021.100050

Figure 2.

Figure 2

Matching-adjusted indirect comparison of progression-free survival with nivolumab plus ipilimumab versus BRAF/MEK inhibitors.

Hazard ratios and confidence intervals were determined using a Cox proportional hazards model analysis.

CI, confidence interval; DAB+TRAM, dabrafenib plus trametinib; ENCO+BINI, encorafenib plus binimetinib; HR, hazard ratio; NIVO+IPI, nivolumab plus ipilimumab; PFS, progression-free survival; VEM+COBI, vemurafenib plus cobimetinib.